Astra goes early in small cell
The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.
Merck makes haste to catch up in KRAS
The company is setting up another battle with Bristol Myers Squibb, while Amgen has different plans.
Nuvation takes the battle to Nuvalent
The takeover of AnHeart centres on advancing the latter’s targeted lung cancer project taletrectinib.
Yervoy delivers a surprise in liver cancer
Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.
Deal analysis part one – the bad
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
